Nanocrystalline silver for treatment of otomycosis- A Retrospective study

Document Type : Original


1 Department of Otorhinolaryngology, Dr. D.Y. Patil Medical college and Hospital, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, India

2 Department of ENT, Professor, Dr DY Patil Medical college, DPU

3 Department Of ENT, MS ENT Resident, DR DY Patil Medical College, Research Centre, DPU

4 Department of ENT, Junior Resident, Dr DY Patil Medical college, DPU


Introduction: Otomycosis is the common infection of ear caused by fungus generallyfound in tropical and subtropical countries where hot and humid conditions assist these types of infections. Also, the recurrence rate of these infections is high and there is limited therapeutic options,which makes its management challenging. The purpose of our study was to determine the antifungal properties of nanocrystalline silveron patients with otomycosis.

Materials and Methods:The study was carried out in Pune (India) at the Dr. D.Y. Patil Medical college, Hospital and research centre in the department of Ear Nose Throat & Head over a period of one year (2019 -2020). Our study constitutes 100 patients,(58 male and 42 female),with clinicallydiagnosed otomycosis were treated using nanocrystalline silver gel soaked Gelfoam.

Results: The Patients which were included in our study were in theage group of 18 to 60 years with highest prevalence in male (58%) aged 30 to 45 years.There were a greater number of cases of infection coming to the hospitali.e., 62 casesduring wet season compare to dry season which were 38 cases. Most common fungus encountered belonged to genus Aspergillus (55%) followed by Candida (45%). 89% of the patients (70% within 5 to 6 days and 19% from 7 to 14 days) symptomatically improved.

Conclusion: Use of Nanocrystalline silver cured most of the patients (89%) within 14 days. Treating Otomycosis patients with Nanocrystalline silver showed beneficial results. Study with large sample should be conducted to validate the benefits of Nanocrystalline silver


Main Subjects

  1. Desai DKJ, Malek DSS, Italia DIK, Jha DS, PandyaV, Shah DH. Fungal Spectrum In Otomycosis At Tertiary Care Hospital. NJIRM. 2012;3(5):58-61
  2. Agarwal P, Devi LS. Otomycosis in a Rural Community Attending a Tertiary Care Hospital: Assessment of Risk Factors and Identification of Fungal and Bacterial Agents. J Clin Diagn Res. 2017 Jun; 11(6): DC14-DC18.doi:10. 7860/JCDR/2017/ 10068
  3. Pradhan B, Tuladhar NR, Amatya RM. Prevalence of Otomycosis in outpatient department of otolaryngology in Tribhuvan University Teaching Hospital, Kathmandu, Nepal. Ann Otol Rhinol Laryngol. 2003;112(4):384-7.
  4. S. Abou-halawa, M. A. Khan, A. A. AlRobaee, A. A. Alzolibani, H. A. AlShobaili. Otomycosis with perforated tympanic membrane: self medication with topical antifungal solution versus medicated ear wick. Int J Health Sci (Qassim). 2012 Jan;6(1): 73-77.
  5. A, S Adoga and A, AIduh. Otomycosis in Jos: Predisposing factors and management. African Journal of Medicine and Medical Sciences. 2014 Sep; 43(Suppl 1): 209-213.
  6. Yehia MM, Al-Habib HM, Shehab NM. Otomycosis: a common problem in North Iraq. J Laryngol Otol. 1990;105(5):387-93.
  7. Stern JC, Lucente FE, Shah MK In vitro effectiveness of 13 agents in otomycosis and review of the literature. The Laryngoscope.1988; 98(11): 1173-77.
  8. Jackman A, Ward R, April M, Bent J. Topical antibiotic induced otomycosis. International journal of Pediatric Otorhinolaryngology. 2005;69:857-860.
  9. Pontes ZBVdS, Silva ADF, Lima EdO, Guerra MdH, Oliveira NMC, Carvalho MdFFP, et al. Otomycosis: a retrospective study. Braz J Otorhinolaryngol. 2009;75(3):367-70.
  10. Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical feathers and treatment implications. Otolaryngology. 2006;135(5):787-791.
  11. Mohammad T Ismail, Abeer Al-Kafri, Mazen Ismail. Otomycosis in Damascus, Syria: Etiology and clinical features. Current Medical Mycology. 2017, 3(3): 27-30
  12. Kiakojori K, Jamnani NB, Khafri S, Omran SM. Assessment of response to treatment in patients with otomycosis. Iranian journal of Otorhinolaryngology 2018 Jan;vol30(96): 41-47.
  13. Gharaghani M, Seifi Z, Mahmoudabadi AZ. Otomycosis in Iran: a review. Mycopathologia 2015; 179(5-6):415-424.
  14. Prasad SC, Kotigadde S, Shekhar M, Thada ND, Prabhu P, D’Souza T, et al. Primary otomycosis in the Indian subcontinent: predisposing fators, microbiology, and classification. Int J Microbiol. 2014; 2014:636493.
  15. Anwar K, Gohar MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pak J Med Sci. 2014 May-Jun; 30(3): 564-67.
  16. Hurst WB. Outcome of 22 cases of perforated tympanic membrane caused by otomycosis. J Laryngol Otol. 2001 Nov;115(11):879-80.
  17. Jaiswal SK. Fungal infection of ear and its sensitivity pattern. Indian J Otolaryngol. 1990; 42:19-22.
  18. Kaur RK, Mittal N, Kakkar M, Aggarwal AK, Mathur MD. Otomycosis: a clinico mycologic study. Ear Nose Throat J. 2000;79(8):606-9.


  1. EJJ Mallmann, FA Cunha, BNMF Castro, AM Maciel, EA   Menezes,  PBA    Antifungal


activity of silver nanoparticles obtained by green synthesis. Rev. Inst. Med. Trop. Sao Paulo. March April 2015; 57(2):165-167.

  1. Gheorghe DC, Niculescu AG, Bîrcă AC, Grumezescu AM. Nanoparticles for the Treatment of Inner Ear Infections. Nanomaterials (Basel). 2021 May 17;11(5):1311. doi: 10.3390/nano11051311. PMID: 34067544; PMCID: PMC8156593.
  2. Shenashen MA, El-Safty SA, Elshehy EA. Synthesis, Morphological control, properties of silver nanoparticles in potential applications. Particle and Particle Systems Characterization. 2014; 31(3): 293-316.
  3. M Banach, R Szczyglowska, J Pulit, M Bryk. Building materials with antifungal efficacy enriched with silver nanoparticles. Chemical Science Journal 2014; 5(1): 1-5.
  4. Mohammad RM, Zahra NY, Masoud Y, Mohammad HN. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Braz J Otorhinolaryngol. Jul-Aug 2018; 84(4):404-409.
  5. Van Hasselt P, Gudde H. Randomized controlled trial on the treatment of otitis externa with one per cent silver nitrate gel. J Laryngol Otol. 2004 Feb; 118(2):93-6.
  6. Zaror L, Fischman O, Suzuki FA, Felipe RG. Otomycosis in Sao Paulo. Rev Inst Med Trop Sao Paulo. 1991; 33(3):169-73.
  7. Keyvan K, Nasim BJ, Soraya K, Saeid MO. Assessment of Response to Treatment in Patients with Otomycosis. Iranian Journal of Otorhino- laryngology, Jan 2018; 30(1), Serial No.96: 41-47.
  8. Paulose KO, Al-Khalifa S, Shenoy P. Mycotic infection of the ear otomycosis): a prospective study. J Laryngol Otol. 1989; 103:3-5.
  9. Kim KJ, Sung WS, Suh BK, Moon SK, Choi JS, Kim JG, et al. Antifungal activity and mode of action of silver nano-particles on Candida albicans. Biometals. 2009; 22: 235-42.
  10. A Nasrollahi, KH Pourshamsian, P Mansourkiaee. Antifungal property of silver nanoparticles on some fungi. International Journal of Nano Dimension. 2011; 1(3):233-239.